Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis

This phase II #ClinicalTrial reports that #Camrelizumab + #Apatinib and #Chemotherapy yields high response rates & manageable safety in #TNBC, with #Biomarker analyses enabling prediction & evaluation of treatment efficacy. #Medsky
#STTT #OpenAccess: doi.org/10.1038/s413...

Combining #camrelizumab and #apatinib with #chemotherapy showed strong efficacy, manageable toxicity, and robust immune activation, highlighting its promise as an effective #NeoadjuvantTherapy. #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

The NASCA regimen—surufatinib, #camrelizumab, nab-paclitaxel, and S-1—achieved superior response and #progressionfreesurvival in #metastatic #PancreaticDuctalAdenocarcinoma, with immune and #biomarker profiling predicting improved outcomes. #medsky

#STTT: doi.org/10.1038/s413...

This study shows that #camrelizumab plus #apatinib with SOX, followed by maintenance treatment, achieved favorable survival outcomes, highlighting this combination as a promising treatment option in AFP-G/GEJ #adenocarcinoma. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Induction with #etoposide and #carboplatin (EC), followed by #camrelizumab, apatinib and EC, and then maintenance with #camrelizumab and apatinib shows promising #antitumor activity in #ESSCLC. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma This randomized trial assesses the effect of adjuvant therapy with camrelizumab after chemoradiotherapy on 3-year event-free survival among patients with locoregionally advanced nasopharyngeal carcino...

Bloqueo coadyuvante de PD-1 con camrelizumab mejora la supervivencia libre de eventos con una toxicidad manejable en pacientes con cáncer nasofaríngeo locorregionalmente avanzado #NPC #camrelizumab jamanetwork.com/journals/jam...

⁦@US_FDA⁩ issued a complete response letter to ⁦@ElevarThera⁩ and its parent company due to inability to fully evaluate manufacturing of #camrelizumab
Intent is to reapply for NDA once issues resolved to regulators satisfaction
#livertwitter ...

Is #Rivoceranib + #camrelizumab headed for #HCC @US_FDA approval? The near future will tell #LiverTwitter www2.onclive.com/view/fda-holds-pre-nda-m... via @onclive

@ILCAnews Drs. Tim Meyer @ucl and Katie Kelley @UCSFMedicine review the current state of #HCC systemic therapy #sorafenib #lenvatinib #cabozantinib #pembrolizumab #atezolizumab #bevacizumab #durvalumab #tremelimumab #camrelizumab #tislelizumab #rivoceranib #ilca22

Could third time be the charm for a Chinese manufactured IO drug? #camrelizumab apparently on track for ⁦@US_FDA⁩ review based on 1L Ph3 data in #HCC in combination with TKI #apatinib #HCCTwitter ...